ClinicalTrials.Veeva

Menu
F

Fundacion Respirar | Clinical Independency Research

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Nivolumab
Bemarituzumab
LY3009104
Baricitinib
Povorcitinib

Parent organization

This site is a part of Fundacion Respirar

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 3 total trials

A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata (BRAVE-AA2)

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Enrolling
Moderate to Severe Asthma
Drug: ICS-LABA
Other: placebo
Locations recently updated

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Enrolling
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Other: Placebo
Drug: Nivolumab

Trial sponsors

Amgen logo
Incyte logo
Lilly logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems